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Background
Alzheimer’s disease (AD) is the most common adult
form of dementia.1 It is an age-associated neurodegen-
erative disorder pathologically characterized by the
abnormal accumulation of intracellular neurofibrillary
tangles and extra cellular amyloid plaques in selected
brain regions. Donepezil is a cholinesterase inhibitor
currently being used in the treatment of Alzheimer’s
disease is metabolized via CYP2D6 enzymes. The pre-
sent study was undertaken to investigate CYP2D6*4
polymorphism on the serum concentration of Donepezil
with responders and non-responders to Alzheimer’s
patients.
Materials and methods
40 Alzheimer’s patients with responders to Donezepil
drug and 40 Alzheimer’sp a t i e n t sw i t hn o n - r e s p o n d e r s
to donezepil drug were investigated for CYP2D6*4 poly-
morphism using polymerase chain reaction - restriction
fragment polymorphisms (PCR-RFLP). Allele frequencies
were derived from genotypic data. Drug responders -
non-responders’ comparisions were made using Chi-
Square tests. Deviations from the Hardy -Weinberg
equilibrium were also tested. Drug levels of Donezepil
were determined using HPLC method.
Results
The CYP2D6*4 Polymorphism was seen to be in
Hardy - Weinberg equilibrium and showed significant
allelic association and genotypic association between
responders and non-responders of donezepil. Genotypic:
P = 0.05; OR = 0.39 (0.13-1.15), Allelic: P = 0.008;
OR = 2.79(1.20-6.58).
Conclusions
O u rf i n d i n gs u g g e s tt h a tt h eC Y P 2 D 6* 4g e n e t i cp o l y -
morphism may be associated with the individual differ-
ences in donezepil metabolism. An individualized
dosage regimen design incorporating such genetic infor-
mation would help to increase the clinical efficacy of
donezepil in Alzheimer’s patients.
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